Reversal Of Fortune? Vioxx Recall Presents Opportunity For NSAID Makers
This article was originally published in The Tan Sheet
Executive Summary
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)
You may also be interested in...
Sen. Grassley’s Proposed Drug Safety Office Would Have Labeling Authority
Sen. Charles Grassley (R-Iowa) will propose legislation creating an independent drug safety office at FDA that would have authority to alter drug labeling and possibly suspend direct-to-consumer advertising
Sen. Grassley’s Proposed Drug Safety Office Would Have Labeling Authority
Sen. Charles Grassley (R-Iowa) will propose legislation creating an independent drug safety office at FDA that would have authority to alter drug labeling and possibly suspend direct-to-consumer advertising
Sen. Grassley’s Proposed Drug Safety Office Would Have Labeling Authority
Sen. Charles Grassley (R-Iowa) will propose legislation creating an independent drug safety office at FDA that would have authority to alter drug labeling and possibly suspend direct-to-consumer advertising